Evaluation of circulating microRNAs-211 and 25 as diagnostic biomarkers of colorectal cancer
- PMID: 34132944
- DOI: 10.1007/s11033-021-06493-9
Evaluation of circulating microRNAs-211 and 25 as diagnostic biomarkers of colorectal cancer
Abstract
Colorectal cancer is one of the most prevalent and deadly cancers worldwide. MicroRNAs are short single stranded non-coding RNAs that play important roles in carcinogenesis, tumor growth and tumor survival. Circulating microRNAs are increasingly becoming efficient and important biomarkers for several types of cancers. Herein, we aim to evaluate the diagnostic potentials of plasma microRNA-211 and microRNA-25 in colorectal cancer patients. Forty-four patients diagnosed with colorectal cancer and 40 healthy controls were recruited for the present study. Expressions of circulating microRNAs -211 and 25 were assessed by quantitative real-time polymerase chain reaction (RT-qPCR). Expression of transforming growth factor-beta, a key factor in tumorigenesis and a key inducer of epithelial to mesenchymal transition was assessed by enzyme-linked immunosorbent assay (ELISA) in patients' tissue and plasma. Our results demonstrated upregulated expressions of plasma microRNAs-211 and 25 correlated with the high transforming growth factor-beta (TGF-β1) expression in patients. In addition, plasma levels were positively correlated with lymph node metastasis. Moreover, receiver operating characteristic analysis demonstrated the reliability of microRNAs-211 and 25 for discriminating colorectal cancer patients from healthy individuals. MicroRNA-211 and microRNA-25 might have a tumorigenic role in colorectal cancer and their plasma levels could be potential biomarkers in its diagnosis.
Keywords: Circulating microRNAs; Colorectal cancer; TGF-β.
References
-
- Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jansen L et al (2017) Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer 140(1):176–187. https://doi.org/10.1002/ijc.30433 - DOI - PubMed
-
- Strasser K, Birnleitner H, Beer A, Pils D, Gerner MC et al (2019) Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile. Oncoimmunology 8(2):e1537693. https://doi.org/10.1080/2162402x.2018.1537693 - DOI - PubMed
-
- Lampis A, Hahne JC, Hedayat S, Valeri N (2020) MicroRNAs as mediators of drug resistance mechanisms. Curr Opin Pharmacol 54:44–50. https://doi.org/10.1016/j.coph.2020.08.004 - DOI - PubMed
-
- Jiang M, Li X, Quan X, Li X, Zhou B (2019) MiR-92a Family: a novel diagnostic biomarker and potential therapeutic target in human cancers. Front Mol Biosci. https://doi.org/10.3389/fmolb.2019.00098 - DOI - PubMed - PMC
-
- Bracken CP, Scott HS, Goodall GJ (2016) A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet 17(12):719–732. https://doi.org/10.1038/nrg.2016.134 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous